These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 20530719)

  • 1. Continuous docetaxel chemotherapy improves therapeutic efficacy in murine models of ovarian cancer.
    De Souza R; Zahedi P; Moriyama EH; Allen CJ; Wilson BC; Piquette-Miller M
    Mol Cancer Ther; 2010 Jun; 9(6):1820-30. PubMed ID: 20530719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
    Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
    PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy dosing schedule influences drug resistance development in ovarian cancer.
    De Souza R; Zahedi P; Badame RM; Allen C; Piquette-Miller M
    Mol Cancer Ther; 2011 Jul; 10(7):1289-99. PubMed ID: 21551263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An injectable depot system for sustained intraperitoneal chemotherapy of ovarian cancer results in favorable drug distribution at the whole body, peritoneal and intratumoral levels.
    Zahedi P; Stewart J; De Souza R; Piquette-Miller M; Allen C
    J Control Release; 2012 Mar; 158(3):379-85. PubMed ID: 22154933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
    Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
    Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1.
    Liu E; Liu Z; Zhou Y
    Int J Clin Exp Pathol; 2015; 8(4):3803-10. PubMed ID: 26097562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
    Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
    Kim TJ; Ravoori M; Landen CN; Kamat AA; Han LY; Lu C; Lin YG; Merritt WM; Jennings N; Spannuth WA; Langley R; Gershenson DM; Coleman RL; Kundra V; Sood AK
    Cancer Res; 2007 Oct; 67(19):9337-45. PubMed ID: 17909042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma.
    Zhao Y; Cao J; Melamed A; Worley M; Gockley A; Jones D; Nia HT; Zhang Y; Stylianopoulos T; Kumar AS; Mpekris F; Datta M; Sun Y; Wu L; Gao X; Yeku O; Del Carmen MG; Spriggs DR; Jain RK; Xu L
    Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2210-2219. PubMed ID: 30659155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
    Sun X; Lou LG; Sui DH; Wu XH
    Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cabazitaxel regimens inhibit the growth of prostate cancer cells and enhances the anti-tumor properties of PEDF with various efficacy and toxicity.
    Jarvis C; Nelius T; Martinez-Marin D; Sennoune SR; Filleur S
    Prostate; 2018 Sep; 78(12):905-914. PubMed ID: 29749077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
    Liu G; Taylor SA; Marrinan CH; Hsieh Y; Bishop WR; Kirschmeier P; Long BJ
    Int J Cancer; 2009 Dec; 125(11):2711-20. PubMed ID: 19530253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docetaxel influences autocrine of transforming growth factors and induces apoptosis in human ovarian cancer cell line AO.
    Zhang Y; Hu YL; Cheng YY
    Chin Med Sci J; 2006 Sep; 21(3):204. PubMed ID: 17086747
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination drug delivery strategy for the treatment of multidrug resistant ovarian cancer.
    Zahedi P; De Souza R; Huynh L; Piquette-Miller M; Allen C
    Mol Pharm; 2011 Feb; 8(1):260-9. PubMed ID: 21166459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
    Henry JY; Lu L; Adams M; Meyer B; Bartlett JB; Dalgleish AG; Galustian C
    Prostate; 2012 Jun; 72(8):856-67. PubMed ID: 21968939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential platelet levels affect response to taxane-based therapy in ovarian cancer.
    Bottsford-Miller J; Choi HJ; Dalton HJ; Stone RL; Cho MS; Haemmerle M; Nick AM; Pradeep S; Zand B; Previs RA; Pecot CV; Crane EK; Hu W; Lutgendorf SK; Afshar-Kharghan V; Sood AK
    Clin Cancer Res; 2015 Feb; 21(3):602-10. PubMed ID: 25473001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
    Miller RE; Roudier M; Jones J; Armstrong A; Canon J; Dougall WC
    Mol Cancer Ther; 2008 Jul; 7(7):2160-9. PubMed ID: 18606716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Docetaxel: promising and novel combinations in ovarian cancer.
    Mäenpää JU
    Br J Cancer; 2003 Dec; 89 Suppl 3(Suppl 3):S29-34. PubMed ID: 14661044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of combining docetaxel and cyclooxygenase-2 inhibitors on proliferation and apoptosis in epithelial ovarian cancer.
    Munkarah AR; Ali-Fehmi R; Jiang JZ; Elhammady E; Malone JM; Saed GM
    Anticancer Drugs; 2007 Sep; 18(8):889-96. PubMed ID: 17667594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.